阿司匹林联合氯吡格雷治疗短暂性脑缺血发作的临床效果分析

The efficacy and safety analysis of aspirin plus clopidogrel for TIA

目的探讨阿司匹林联合氯吡格雷治疗短暂性脑缺血发作（TIA）的有效性和安全性。方法选择我院2011年9月~2014年9月收治的短暂性脑缺血发作患者45例,入组患者随机分配到阿司匹林联合氯吡格雷组（治疗组）及阿司匹林组（对照组）,观察指标包括治疗后的临床疗效及其安全性。结果治疗14 d后,治疗组复发1例,总有效率为95.5%,对照组复发3例,总有效率为82.6%;治疗3个月后,治疗组未发现进展为脑梗死患者,对照组进展为脑梗死患者1例,治疗组临床疗效显著优于对照组。治疗组的PT、APTT及FIB改变均较对照组明显。两组均未出现严重不良反应。结论早期双重抗血小板治疗短暂性脑缺血发作可减少TIA患者复发,安全性较高。

Objective To investigate efficacy and safety of aspirin plus clopidogrel for TIA. Methods A total of 45 TIA patients from September 2011 to September 2014 in our hospital were assigned to aspirin plus clopidogrel group（treatment group） and aspirin group（control group）. The efficacy and safety were analyzed. Results After 14 days, 1 recurrence case was observed in treatment group with effective rate of 95.5%, while 3 cases were observed in control group with effective rate of 82.6%. 3 months later, no patient progressed to acute cerebral infarction in treatment group, while one patient progressed in control group. the clinical effect of treatment group was superior to that in the control group.Additionally, the changes of PT, APTT and FIB in treatment group were more remarkable than that in control group.There was no adverse reaction in two groups. Conclusion Dual antiplatelet therapy treatment with TIA can reduce relapse with high security.